Profitability metrics were largely in line with expectations previously communicated. Lombardi said gross margin was 55.5% and adjusted diluted EPS was $1.14, consistent with guidance given on the company’s second-quarter call. Sacco said adjusted diluted EPS declined from $1.22 in the prior-year quarter due to lower sales, the timing of advertising and marketing spending, and higher G&A costs.Management characterized the consumer backdrop as challenging and dynamic, citing ongoing changes in where consumer ...

Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Company ParticipantsCarla Casella - Managing DirectorChris Sacco - CFO and COOMitchell Pinheiro - Director of Fundamental Equity ResearchPhil Terpolilli - VP of Investor Relations and TreasuryRon Lombardi - Chairman, President and CEOConference Call ParticipantsJon Anderson - Partner and Research AnalystKeith Davis - Senior Financial AnalystRupesh Parikh - Managing Director and Senior AnalystSusan Anderson - Managing ...

Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Company ParticipantsCarla Casella - Managing DirectorChris Sacco - CFO and COOMitchell Pinheiro - Director of Fundamental Equity ResearchPhil Terpolilli - VP of Investor Relations and TreasuryRon Lombardi - Chairman, President and CEOConference Call ParticipantsJon Anderson - Partner and Research AnalystKeith Davis - Senior Financial AnalystRupesh Parikh - Managing Director and Senior AnalystSusan Anderson - Managing ...

Prestige Consumer Healthcare (NYSE:PBH) Q3 2026 Earnings call February 05, 2026 08:30 AM ET Speaker1day and thank you for standing by. Welcome to the third quarter, 2026, Prestige Consumer Healthcare Inc. earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your ha ...

Third Quarter FY 26 Results February 5, 2026 Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, adjusted diluted EPS, and free cash flow; the Company's ability to execute on its brand-building strategy to drive organic growth; the Company's ability to maximize shareholder value an ...

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.30%. A quarter ago, it was expected that this medicine distributor would post earnings of $0.97 per share when it actually produced earnings of $1.07, delivering a surprise of +10.31%.Over the last f ...

Last time I covered Premium Brands ( PBH:CA ), I ran the numbers on management’s $10 billion revenue goal for FY 2027 and got to about $110 per share already discounted to present value.I’m an equity analyst and founder of Goulart’s Restaurant Stocks, a research firm focused on the U.S. restaurant industry — from quick-service and fast casual to fine dining and niche concepts. I lead all thematic research and valuation efforts, applying advanced financial modeling, sector-specific KPIs, and strategic insigh ...

Revenue Performance - Total revenues for the three months ended December 31, 2025 were $283.4 million, a decrease of $6.9 million, or 2.4%, compared to the same period in 2024[98]. - Total revenues for the nine months ended December 31, 2025 were $807.1 million, a decrease of $34.2 million, or 4.1%, compared to $841.2 million for the same period in 2024[117]. - North American OTC Healthcare segment revenues decreased by $3.2 million, or 1.4%, primarily due to declines in Eye & Ear Care, Analgesics, and Women's Health categories[100]. - North American OTC Healthcare segment revenues decreased by $32.0 million, or 4.5%, primarily due to a decline in sales in the Eye & Ear Care category[118]. - International OTC Healthcare segment revenues decreased by $3.6 million, or 7.1%, mainly due to a decline in Eye & Ear Care sales, partially offset by an increase in Women's Health[101]. - International OTC Healthcare segment revenues decreased by $2.1 million, or 1.6%, mainly due to a decrease in sales in the Eye & Ear Care category, partially offset by an increase in Women's Health sales[119]. Profitability Metrics - Gross profit for the three months ended December 31, 2025 decreased by $3.7 million, or 2.3%, compared to the same period in 2024, while gross profit margin remained constant at 55.5%[103]. - Gross profit for the nine months ended December 31, 2025 decreased by $15.2 million, or 3.3%, to $449.3 million, while gross profit margin increased to 55.7% from 55.2%[120]. - Contribution margin for the North American OTC Healthcare segment decreased by $1.9 million, or 1.9%, with a margin of 41.6% in Q3 2025, down from 41.8% in Q3 2024[108]. - Contribution margin for the North American OTC Healthcare segment decreased by $4.2 million, or 1.4%, to $285.8 million, with a margin increase to 42.1% from 40.8%[126]. - Contribution margin for the International OTC Healthcare segment decreased by $3.9 million, or 16.9%, with a margin of 40.4% in Q3 2025, down from 45.2% in Q3 2024[109]. - Contribution margin for the International OTC Healthcare segment decreased by $6.0 million, or 10.7%, to $49.8 million, with a margin decrease to 38.9% from 42.8%[127]. Expenses and Financial Position - General and administrative expenses increased by $5.0 million to $86.2 million for the nine months ended December 31, 2025, compared to $81.2 million for the same period in 2024[128]. - Interest expense, net decreased to $30.9 million for the nine months ended December 31, 2025, from $36.9 million for the same period in 2024, with average indebtedness decreasing to $1.0 billion[130]. - The provision for income taxes increased to $56.4 million for the nine months ended December 31, 2025, compared to $45.8 million for the same period in 2024, with an effective tax rate increase to 29.2% from 21.8%[132]. - Cash and cash equivalents decreased by $35.5 million to $62.4 million as of December 31, 2025, with cash provided by operating activities increasing to $214.8 million[134]. - Net cash provided by operating activities increased to $214.8 million for the nine months ended December 31, 2025, up from $189.7 million for the same period in 2024, reflecting a $25.1 million increase primarily due to working capital timing[135]. - Net cash used in investing activities rose significantly to $133.4 million for the nine months ended December 31, 2025, compared to $14.0 million for the same period in 2024, marking a $119.5 million increase primarily due to acquisitions[136]. - Net cash used in financing activities decreased to $118.0 million for the nine months ended December 31, 2025, down from $170.6 million for the same period in 2024, a reduction of $52.6 million attributed to decreased net debt repayments[137]. - As of December 31, 2025, the company had $1.0 billion in outstanding indebtedness, including $40.0 million on the 2012 ABL Revolver and a borrowing capacity of $146.4 million[138]. - The company must maintain a fixed charge ratio greater than 1.0 to 1.0 for the quarter ended December 31, 2025, and was in compliance with applicable financial covenants[140]. - The company has $400.0 million of 5.125% 2019 senior unsecured notes maturing on January 15, 2028, and $600.0 million of 3.750% 2021 senior unsecured notes maturing on April 1, 2031[141]. Strategic Developments - The acquisition of Pillar5 Pharma, Inc. was completed on December 18, 2025, funded through cash and an asset-based revolving credit facility[89]. - Economic uncertainty continues to impact supply chains, labor availability, and input costs, potentially affecting product demand and operational performance[92]. - The company has observed a shift in consumer purchasing patterns towards online channels, influencing retailer purchasing strategies[92]. - The company reported no material changes to its critical accounting policies during the nine months ended December 31, 2025[142]. - The company anticipates compliance with financial and restrictive covenants during the next twelve months based on normal operations[140]. - The company faces various risks including supply chain disruptions, competition, and dependence on third-party manufacturers[146]. - The company’s exposure to market risk has not changed materially since March 31, 2025[149].

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results Reported revenues for the first nine months of fiscal 2026 totaled $807.1 million and compared to revenues of $841.2 million for the first nine months of fiscal 2025. Revenues decreased 4.1% versus the prior year comparable period and 3.9% excluding the impact of foreign currency. The revenue performance for the first nine months reflected the limited ability to supply strong demand for Clear Eyes® as w ...

Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial r ...